Acne

Derm-Biome Pharmaceuticals prepares to begin IND-enabling studies for DB-007-4, a potential best-in-class treatment for inflammatory skin diseases

Retrieved on: 
Tuesday, February 27, 2024

Toxicology studies are an essential part of drug development as they help to evaluate the potential safety and toxicity of a drug candidate before it is tested on humans.

Key Points: 
  • Toxicology studies are an essential part of drug development as they help to evaluate the potential safety and toxicity of a drug candidate before it is tested on humans.
  • There is a real need for skin disease drugs that offer high efficacy and a low risk of adverse effects with long-term use.
  • For conditions like AD, an inflammatory skin disease that affects up to 25% of babies and young children, there is a need for safer treatment options.
  • DB-007-4 is a topical multi-disease treatment that targets important pathways that play a vital role in the development of inflammatory skin diseases while being well-tolerated by skin.

Dr. Suzan Obagi Appointed as Chief Medical Director at Obagi Cosmeceuticals, a Subsidiary of Waldencast plc.

Retrieved on: 
Tuesday, February 20, 2024

Obagi is a subsidiary of Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform and publicly listed company.

Key Points: 
  • Obagi is a subsidiary of Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform and publicly listed company.
  • Dr. Suzan Obagi is a world-renowned, leading board-certified dermatologist and cosmetic surgeon, recognized for her groundbreaking contributions to the fields of dermatology, cosmetic surgery, and skincare.
  • “I am thrilled to be taking on a more formal role at Obagi as the Company’s first-ever Chief Medical Director,” said Dr. Suzan Obagi.
  • "We are honored to deepen our relationship with Dr. Suzan Obagi as she assumes the role of Obagi’s inaugural Chief Medical Director," said Jordan Meyer, President of Obagi.

Galderma Announces Record 2023 Net Sales of Over 4 B USD and Significant Core EBITDA Margin Expansion

Retrieved on: 
Thursday, February 29, 2024

2023 margin expansion was driven by gains from premiumization, structural cost savings, and operating expenses leverage, partially offset by nemolizumab investments.

Key Points: 
  • 2023 margin expansion was driven by gains from premiumization, structural cost savings, and operating expenses leverage, partially offset by nemolizumab investments.
  • On 26 June 2023, Galderma announced a private placement of approximately 1 B USD from a group consisting of current shareholders, new investors, as well as management.
  • Cetaphil, with over 75 years of heritage in sensitive skincare, surpassed a record 1 B USD in net sales in 2023.
  • In 2023, Galderma further consolidated its ESG profile by rolling out a dedicated executive-level ESG oversight and instituting the ESG Council.

Galderma to Showcase Latest Updates From Its Broad, Innovative and Leading Dermatology Portfolio at the 2024 American Academy of Dermatology Annual Meeting

Retrieved on: 
Wednesday, February 28, 2024

Galderma, the pure-play dermatology category leader, will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) Annual Meeting from March 8-12, 2024, highlighting its broad, innovative and leading dermatology portfolio.

Key Points: 
  • Galderma, the pure-play dermatology category leader, will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) Annual Meeting from March 8-12, 2024, highlighting its broad, innovative and leading dermatology portfolio.
  • “Our vast presence at AAD combines new data, novel educational activities and patient perspectives, demonstrating how we are putting our commitment to addressing the needs of the dermatology community into action.
  • The event is taking place on Saturday, March 9, in the Pacific Ballroom 21-26, Marriott Marquis San Diego Marina, from 7:00 to 9:00 PM PST.
  • *All presenters are paid consultants or employees of Galderma.

Makers of Proactiv, Clearasil, and Others Sued in Benzoyl Peroxide Acne Product Class Action

Retrieved on: 
Friday, March 8, 2024

LOS ANGELES, March 8, 2024 /PRNewswire/ -- Wisner Baum filed multiple class actions alleging several companies sold benzoyl peroxide (BPO) acne products without warning consumers that they contain unsafe levels of benzene, a potent human carcinogen.

Key Points: 
  • Lab testing found numerous acne products formulated with benzoyl peroxide, including face washes, creams, and spot treatments, degrade to cancer-causing benzene under normal use and handling.
  • LOS ANGELES, March 8, 2024 /PRNewswire/ -- Wisner Baum filed multiple class actions alleging several companies sold benzoyl peroxide (BPO) acne products without warning consumers that they contain unsafe levels of benzene, a potent human carcinogen.
  • Class action attorneys Stephanie B. Sherman and R. Brent Wisner filed the complaints (Example Case: Howard et al.
  • "Our clients never would have purchased these products had they known they were exposing themselves to a dangerous carcinogen."

MellingMedical to Deliver the Groundbreaking Accure Acne Laser to Federal Health Facilities

Retrieved on: 
Wednesday, March 6, 2024

ALEXANDRIA, Va., March 6, 2024 /PRNewswire/ -- MellingMedical today announced a new distribution relationship with Accure Acne, Inc., a pioneer in the development of innovative solutions for the treatment of acne. Under the terms of their agreement, MellingMedical can offer the company's Accure Laser™ System to board-certified dermatologists in federal health facilities who are engaged in treating mild to severe inflammatory acne vulgaris. As an SBA-Verified Service-Disabled Veteran-Owned Small Business (SDVOSB), MellingMedical offers a preferential pathway into the federal health system for providers like Accure.

Key Points: 
  • ALEXANDRIA, Va., March 6, 2024 /PRNewswire/ -- Melling Medical today announced a new distribution relationship with Accure Acne, Inc. , a pioneer in the development of innovative solutions for the treatment of acne.
  • Under the terms of their agreement, MellingMedical can offer the company's Accure Laser™ System to board-certified dermatologists in federal health facilities who are engaged in treating mild to severe inflammatory acne vulgaris.
  • As an SBA-Verified Service-Disabled Veteran-Owned Small Business (SDVOSB), MellingMedical offers a preferential pathway into the federal health system for providers like Accure.
  • MellingMedical introduces Accure Acne's groundbreaking laser technology to patients in the federal health system.

Sun Pharma Launches WINLEVI® (clascoterone) Cream 1% Connected TV (CTV) Ad Campaign with Dr. Sandra Lee (a.k.a. "Dr. Pimple Popper")

Retrieved on: 
Wednesday, March 6, 2024

WINLEVI is the first and only FDA-approved topical acne treatment available in the U.S. that targets sebum production in the skin.

Key Points: 
  • WINLEVI is the first and only FDA-approved topical acne treatment available in the U.S. that targets sebum production in the skin.
  • "We are thrilled to continue our collaboration with Dr. Sandra Lee, whose persona as 'Dr.
  • Pimple Popper' fits well with our use of humorous and relatable content to connect with teens.
  • Additionally, edema, stinging, and burning occurred in >3% of patients and were reported in a similar percentage of subjects treated with vehicle.

The Wound Pros Launches Wound Care Without Walls Program in Nigeria

Retrieved on: 
Monday, March 4, 2024

LOS ANGELES, March 4, 2024 /PRNewswire/ -- Dr. Chris Otiko, co-founder and corporate treasurer at The Wound Pros: https://www.thewoundpros.com, was recently in Abuja, Nigeria's capital, to launch the company's Wound Care Without Walls (WCWW) program and introduce Tetracyte.

Key Points: 
  • The Wound Pros extends its healing services into Nigeria.
  • Promotes Tetracyte product
    LOS ANGELES, March 4, 2024 /PRNewswire/ -- Dr. Chris Otiko, co-founder and corporate treasurer at The Wound Pros: https://www.thewoundpros.com , was recently in Abuja, Nigeria's capital, to launch the company's Wound Care Without Walls (WCWW) program and introduce Tetracyte.
  • Otiko was accompanied by Texas resident Adebola Adefuye, clinical supervisor for The Wound Pros' Complex Wound Management Team.
  • Otiko and Adebola also had strategy discussions with Wound Pros employees in Nigeria, focusing on marketing avenues to launch product sales in Nigeria.

Celluma Light Therapy Announces Launch of Revolutionary Body Contouring Device

Retrieved on: 
Friday, March 1, 2024

TUSTIN, Calif., March 1, 2024 /PRNewswire/ -- BioPhotas, Inc., the market leader in therapeutic LED Light Therapy Devices, announced today the launch of the Celluma CONTOUR, the only FDA-cleared light therapy device treating body contouring, aging skin, and pain management.

Key Points: 
  • TUSTIN, Calif., March 1, 2024 /PRNewswire/ -- BioPhotas, Inc., the market leader in therapeutic LED Light Therapy Devices, announced today the launch of the Celluma CONTOUR, the only FDA-cleared light therapy device treating body contouring, aging skin, and pain management.
  • "The Celluma CONTOUR is the first LED Light Therapy device to be FDA-cleared on an Over-The-Counter basis for body contouring," commented BioPhotas President and CEO, Curtis Cluff.
  • "It is also the only LED light therapy device on the market designed with multiple treatment modes for reducing wrinkles, reducing muscle and joint pain, as well as body contouring in a single device."
  • Low Level Light Therapy (LLLT) for body contouring is a proven, non-invasive technique to reduce the circumference of the hips, waist, and thighs safely and effectively.

Face Reality® Announces Exclusive Partnership with Highly Esteemed Esthetician and Educator, Douglas Preston, Including Sole Distribution of the Preston Comedone Rxtractor®️

Retrieved on: 
Thursday, February 29, 2024

DANVILLE, Calif., Feb. 29, 2024 /PRNewswire/ -- Face Reality® strengthens its position as the #1 Professional Acne Brand by teaming with esteemed Esthetician Douglas Preston of Preston Acne Pros to bring exclusive U.S. distribution of his proprietary Preston Comedone Rxtractor® tool, as well as enhanced acne education and support to estheticians across the United States. By combining these award-winning brands, Face Reality further boosts their authority as a leading force in the industry and continues their mission to deliver clear skin for good via unparalleled expertise and innovation within the acne skincare space.

Key Points: 
  • Douglas Preston of Preston Acne Pros
    As of February 28th, Face Reality Acne Experts now have access to the Preston Comedone Rxtractor® via FaceRealitySkincare.com .
  • The Preston Comedone Rxtractor® and in-person Preston Comedone Rxtractor® training will be available for purchase to licensed skincare professionals at the Face Reality booth.
  • On behalf of Face Reality, Douglas Preston will provide exclusive in-person and online training to Face Reality Certified Acne Experts.
  • Douglas's in-person extraction classes will be exclusively held at Face Reality's training facility in Danville, CA, where Douglas will integrate Preston Comedone Rxtractor® training with the Face Reality Clear Skin Method™.